Today’s AI Top Pick: ARDX

8/10/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · ContrarianARDXBUY NOW8.4 / 108/10/2026

ARDX is the cleanest contrarian bounce setup in the pool. Multi-timeframe alignment is textbook: 4h forecasts +45.6/+43.6/+66.1%, 1d +32.1/+52.6/+42.4%, and 1wk +13.3/+28.5/+29.0% — every horizon on every timeframe points up, with mid/long magnitudes dominating (a real trend-reversal signature, not just noise). Bullish probability is 1.0 with near_term_bullish 0.8. The drawdown looks like capitulation, not a broken trend. RSI is 18.66 (extreme oversold), price sits at pos_in_21bar_range 0% on 4h / 6.92% on 1d / 3.12% on 1wk — that's rock-bottom, meaning downside is largely priced in. The 14d drawdown is -20.9%, but the stock is not making a fresh 21-bar low on the daily (dd only -22.83%), suggesting sellers are exhausting. Combined with a 4h forecast rebound of 45%+ off a base at range-bottom, this is a coiled setup. Fundamentals and news underwrite it. Fundamental score 4.25, recom 1.0 (strong buy), fwdPe 12.96, targetUpsidePct 225%, salesYoY +16.77%, gross margin 93.6%, epsNextY +286.8%. Crucially, the news is a positive tiebreaker rather than a landmine: 'Ardelyx Posts Record Revenue' and TD Cowen reiterated Buy (even while trimming PT to $10 — still huge upside from $4.09). Contrast that with AHCO (down hard on bad week), MYGN/USNA/LII/QDEL/TRIP (all cut guidance), ALHC (lawsuit accounting questions), BETR (CEO exit -34%), and ADTN (new strong-sell listing) — those forecasts are undercut by materially bad news. Why TODAY vs. waiting: pos_in_21bar_range is 0-7% across timeframes, RSI 18.66, and the earnings-driven flush is 2-3 days old with the record-revenue positive already public. Waiting for a bounce risks chasing 15-20% higher into the first target zone. This is the trade-location entry.

Entry zone

$4.00–$4.15 (current $4.09, scale in on any dip toward $3.95)

Stop loss

$3.55 (below the 4h/1d 21-bar low; ~13% risk)

First target

$5.20 (short-term forecast +27% zone; reclaim of mid-range)

Longer target

$6.20–$6.50 (mid/long forecast alignment ~52-66% up; still 30%+ below $10 analyst PT)

Risks

Biotech single-product concentration (XPHOZAH) — any payer/reimbursement setback could re-break the trend
Profit margin -12.35% and roe -38.61%; still cash-burning, so a bad quarter could pressure balance sheet (debtEq 1.72)
Short float 11.07% — squeeze potential is a plus, but also means bearish thesis has believers
TD Cowen trimmed PT to $10 alongside record revenue — sell-side sentiment cooling on top-line at the margin
Broad healthcare sector weakness (multiple names in this pool cut guidance) could cap sector-wide bounce

Honorable mentions

LZBest 1wk stability of the group (recent_21bar +5.29%, already basing). Positive Microsoft Copilot integration catalyst, fwdPe 6.97, PEG 0.57, fundamental_score 4.75. Multi-timeframe forecasts all up (+11/+43/+37 on 1d). Slightly less upside magnitude than ARDX but lower risk.

ALNYHighest fundamental_score in the pool at 8.0 (roe 100.7, profit margin 16.82%, PEG 0.29, salesYoY +95%). 4h/1d forecasts strong (+42-70%), pos_in_range low. Downgraded from #1 because Truist issued pessimistic forecast and 1wk forecast is only +1-7% (bounce may be shallower).

Full ranking (31)

#	Symbol	Verdict	Score	Read
1	ARDX	BUY NOW	8.4	Deep-oversold (RSI 18.66) with all-timeframe forecast alignment, positive record-revenue print, and range-bottom entry.
2	LZ	BUY NOW	7.8	Already basing on weekly (+5.29%), Copilot catalyst, cheap on fwdPe 6.97/PEG 0.57 with 4.75 fundamental score.
3	ALNY	BUY NOW	7.6	Best fundamentals in pool (score 8, PEG 0.29, roe 100.7) with strong 4h/1d bounce forecasts, though weekly forecast muted.
4	PHAT	BUY NOW	7.2	Solid 4h forecasts (+42-50%), analyst Buys reiterated post-earnings, salesYoY +110%, fwdPe 9.26.
5	BAER	BUY NOW	6.9	Affirmed FY26 guidance is a real positive; strong forecasts across all TFs (+50-147% long). Debt (7.81) is the caveat.
6	EBS	BUY PULLBACK	6.7	RSI 17.74 extreme oversold, 4h/1d forecasts +80-133%, recom 1.0, but weekly forecast weaker and dd 48%.
7	TYGO	BUY PULLBACK	6.5	Massive 4h forecast +138% and recom 1.0, but fwdPe 488 signals earnings quality issues and price is $1.23 penny territory.
8	CCB	BUY PULLBACK	6.2	1d forecast +58-107% and insider buying, but 1wk forecast turns NEGATIVE (-20.94%), which is a red flag.
9	OI	BUY PULLBACK	5.9	All-timeframe up forecasts (+37-92%), pos_in_range 0%, fwdPe 4.69, but debtEq 13.02 is dangerous.
10	ALHC	WAIT	5.5	Good fundamentals (score 5.75) but lawsuit-driven accounting questions and Raymond James downgrade cap the setup — weekly forecasts turn negative.
11	MNRO	BUY PULLBACK	5.4	Multi-TF up (+18/+35/+44 on 1d), targetUpside 72.8%, but persistent operational weakness per StockStory.
12	CNTX	WAIT	5.3	Enormous 4h forecast (+347%) but company just dropped its bispecific T-cell engager program — thesis materially weaker.
13	PSN	BUY PULLBACK	5.2	Solid fundamentals (score 4.5, roe 6.12, profitable) but pos_in_range already 22-38% — not at bottom, and PT cuts continue.
14	BV	WAIT	5.0	Modest forecasts (+8-18%) and Morgan Stanley PT cut to $12.50 after earnings reset.
15	CMRC	WAIT	4.9	Strong 4h/1d forecasts (+51-95%) but just cut guidance; refocus story unproven.
16	LII	AVOID	4.7	Cut 2026 EPS guidance, pos_in_range 15-30% (not oversold), forecasts modest (+8-22%) — no edge.
17	INDP	WAIT	4.6	Massive forecasts (+615% weekly) but roe -931, no revenue, no recent news = pure gamble.
18	HSCS	WAIT	4.4	1wk forecast +201% but company doing reverse-merger with Fortitude Mining — dilution/structure risk enormous.
19	NXL	WAIT	4.2	Micro-cap $7.7M with operMargin -3084% — forecast noise, not signal.
20	TDTH	AVOID	4.0	ps 22,178 and profit margin -14,045% — this is a zombie ticker; ignore the forecast.
21	GXAI	WAIT	3.9	$9M micro-cap, no near-term catalysts, forecasts modest (+42-57%).
22	ZONE	AVOID	3.8	near_term_bullish only 0.2, 4h forecast NEGATIVE (-25.2%), and profit margin -4,665%.
23	PHAT_dupe_skip	WAIT	0.0	skip
24	AHCO	AVOID	3.5	'Stock plummeted this week' is a fresh Motley Fool headline — momentum is against the bounce despite strong forecast.
25	ADTN	AVOID	3.4	Added to Zacks Strong Sell list and multiple PT cuts post-Q2 — forecast undercut by fresh negative flow.
26	TRIP	AVOID	3.2	Down 23.9% on weak Q2 with two Underweight PT cuts to $9-10 — falling knife, not exhausted seller.
27	USNA	AVOID	3.1	Lowered guidance and Q2 loss just reported — bounce thesis conflicts with fundamental deterioration.
28	QDEL	AVOID	3.0	Fresh guidance reset amid China headwinds; 1wk forecast even turns negative short-term.
29	MYGN	AVOID	2.8	Cut 2026 revenue outlook and down 49%; fundamental_score 0, Wells Fargo cut PT to $3 vs $3.26 current.
30	XPOF	AVOID	2.6	Missed Q2 by $0.11 EPS and Guggenheim downgraded — near_term_bullish only 0.4.
31	BETR	AVOID	2.2	CEO exit + down 34.2% + 1wk forecasts all NEGATIVE (-46 to -100%) — broken trend, not bounce.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord